Biogen
-
Biogen Idec and Elan receive notification of PDUFA date extension
Biogen Idec and Elan are working with the FDA to help facilitate a timely review of the REMS changes and the sBLA.
Biogen | 20 October 2011
-
Boehringer Ingelheim licenses ProBioGen's GlymaxX technology
Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive licensing agreement regarding ProBioGen’s GlymaxX technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (…
Biogen | 11 August 2011
-
Biogen Idec, Abbott report positive results from trial of daclizumab HYP
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting mult…
Biogen | 09 August 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
Biogen | 04 July 2011
-
Biogen Idec identify novel approach for treatment of multiple sclerosis
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in …
Biogen | 01 July 2011
-
Biogen Idec celebrates World MS Day
Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. The company said it continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the…
Biogen | 25 May 2011
-
Biogen Idec acquires subsidiary of Neurimmune
Biogen Idec has acquired a subsidiary of Neurimmune , which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three…
Biogen | 16 February 2011
-
Measurement of Midkine in blood serum
Biogenes has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum. Furthermore, BioGenes has completed the manufacture of the first batch of MK ELISA kits. Midkine blood test (MK ELISA) has b…
Biogen | 28 December 2010
-
GlymaxX: novel glyco-engineering technology
Probiogen launches its innovative Glyco-Engineering Technology "GlymaxX" for the generation of afucosylated antibodies with strongly increased potency. GlymaxX is a universally and rapidly applicable technology to enhance the ADCC effector funct…
Biogen | 28 November 2010
-
Probiogen Signs Therapeutic Protein Process Development Contract with Virdante
ProBioGen, a technology and service provider for the development and production of biopharmaceutical drug substances, has announced the signing of a contract with Virdante Biopharmaceuticals, a US-based biopharmaceutical development company. The f…
Biogen | 28 May 2010
